Pengjun Liao
Overview
Explore the profile of Pengjun Liao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li S, He W, Yau H, Xie J, Zhu Y, Chen X, et al.
Ren Fail
. 2025 Feb;
47(1):2453006.
PMID: 39995107
Objectives: To compare the efficacy and safety of bortezomib with thalidomide and dexamethasone (BTD) and bortezomib with cyclophosphamide and dexamethasone (BCD) as the initial treatment for renal amyloid light chain...
2.
Wang J, Zhao Y, Liao P, Huang S, Huang Y, Chen S, et al.
Blood Sci
. 2024 Jan;
6(1):e00181.
PMID: 38226018
Amyloid light chain (AL) amyloidosis is a rare plasma cell dyscrasia with dismal prognosis. This study aims to investigate the T-cell immune checkpoint expression patterns in systemic AL amyloidosis and...
3.
Huang S, Zhao Y, Liao P, Wang J, Li Z, Tan J, et al.
Front Oncol
. 2022 Nov;
12:1014904.
PMID: 36439426
V-type immunoglobulin domain-containing suppressor of T cell activation (VISTA) is considered as an immunosuppressive factor and potential therapeutic target for anticancer therapy. However, little is known about VISTA expression and...
4.
Zhang L, Zhou L, Wang Y, Li C, Liao P, Zhong L, et al.
Front Oncol
. 2022 Nov;
12:1057153.
PMID: 36408189
Identifying subgroups of T-cell acute lymphoblastic leukemia (T-ALL) with poor survival will significantly influence patient treatment options and improve patient survival expectations. Current efforts to predict T-ALL survival expectations in...
5.
Wang J, Yang S, Liao P, Zeng L, Ling W, Wan L, et al.
Front Cardiovasc Med
. 2022 Sep;
9:994384.
PMID: 36119749
Background: The t(11;14)(q13;32) is a common chromosome translocation in multiple myeloma (MM), but its prognostic value remains controversial. Immunoglobulin light chain amyloidosis is commonly secondary to multiple myeloma, which can...
6.
Zhao Y, Liao P, Huang S, Deng T, Tan J, Huang Y, et al.
Exp Hematol Oncol
. 2022 Mar;
11(1):12.
PMID: 35246241
Previous studies have shown increased aberrant expression of immune checkpoint (IC) proteins, such as programmed cell death receptor-1 (PD-1) and T cell immunoglobulin mucin-domain-containing-3 (Tim-3) on T cells from patients...
7.
Tan Z, Yang Y, Wu X, Li S, Li L, Zhong L, et al.
Int J Cardiovasc Imaging
. 2022 Feb;
38(7):1519-1532.
PMID: 35113283
Systemic light-chain (AL) amyloidosis is characterized by the aggregation of misfolded immunoglobulin light chain, predominantly infiltrating in the heart, including left atrium (LA). LA remodeling, such as increased interatrial septal...
8.
Lai P, Chen X, Qin L, Jiang Z, Luo C, Huang X, et al.
Leukemia
. 2020 Jul;
34(10):2790-2793.
PMID: 32632097
No abstract available.
9.
Pang Y, Geng S, Zhang H, Lai P, Liao P, Zeng L, et al.
Oncol Lett
. 2019 Oct;
18(5):4457-4466.
PMID: 31611955
Mesenchymal stem cells (MSCs) derived from myelodysplastic syndromes (MDSs) have been demonstrated to accelerate the progression of MDS. However, whether the phenotype of MSCs derived from MDS (MDS-MSCs) may be...
10.
Pang Y, Deng C, Geng S, Weng J, Lai P, Liao P, et al.
Am J Transl Res
. 2017 Aug;
9(7):3462-3468.
PMID: 28804562
Myelodysplastic syndrome (MDS) predominantly occurs in aging people. Over the past decades, the cellular and molecular pathologies of MDS cells have been intensively investigated. However, how the bone marrow stromal...